標(biāo)題: Titlebook: Novel Therapeutics for Rare Lymphomas; Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra [打印本頁] 作者: 螺絲刀 時(shí)間: 2025-3-21 16:50
書目名稱Novel Therapeutics for Rare Lymphomas影響因子(影響力)
書目名稱Novel Therapeutics for Rare Lymphomas影響因子(影響力)學(xué)科排名
書目名稱Novel Therapeutics for Rare Lymphomas網(wǎng)絡(luò)公開度
書目名稱Novel Therapeutics for Rare Lymphomas網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Novel Therapeutics for Rare Lymphomas被引頻次
書目名稱Novel Therapeutics for Rare Lymphomas被引頻次學(xué)科排名
書目名稱Novel Therapeutics for Rare Lymphomas年度引用
書目名稱Novel Therapeutics for Rare Lymphomas年度引用學(xué)科排名
書目名稱Novel Therapeutics for Rare Lymphomas讀者反饋
書目名稱Novel Therapeutics for Rare Lymphomas讀者反饋學(xué)科排名
作者: 憤怒事實(shí) 時(shí)間: 2025-3-21 23:17 作者: 沙發(fā) 時(shí)間: 2025-3-22 00:27
Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,e Ki-1 antibody binding to Reed-Sternberg cells in Hodgkin lymphoma (Stein et al., Blood 66(4):848–858, 1985). Since it has high expression within Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), variable expression in other non-Hodgkin lymphoma subgroups, and limited expression in n作者: 一起平行 時(shí)間: 2025-3-22 05:26 作者: 敘述 時(shí)間: 2025-3-22 12:40 作者: 極少 時(shí)間: 2025-3-22 15:01 作者: 敲竹杠 時(shí)間: 2025-3-22 19:32 作者: 烤架 時(shí)間: 2025-3-23 00:40
Novel Agents in Primary Central Nervous System Lymphoma,te-based therapies has improved patient outcomes in the first-line setting, the prognosis of relapsed and refractory disease is poor. PCNSL has a unique pathophysiology and gene expression profile, making it more amenable to novel targeted and immunotherapeutic agents. Therapies such as ibrutinib, n作者: Outmoded 時(shí)間: 2025-3-23 05:16 作者: Bouquet 時(shí)間: 2025-3-23 09:04
Extranodal NK/T-Cell Lymphoma,and is characterized by localized lesions involving the nose, nasopharynx, or oropharynx. Extra-nasal disease is less common and generally more aggressive. The immunophenotype of ENKTCL is unique, with most cases expressing NK-cell markers (CD2+, cytoplasmic CD3+, and CD56+). Treatment options for l作者: gastritis 時(shí)間: 2025-3-23 12:03
Anaplastic Large Cell Lymphoma,naplastic lymphoma kinase-positive (ALK-positive) ALCL generally having a better prognosis and occurring in younger patients than ALK-negative ALCL. Multiagent chemotherapy, now with the addition of brentuximab vedotin, an anti-CD30 monoclonal antibody-drug conjugate, is the recommended initial ther作者: 嚴(yán)厲批評(píng) 時(shí)間: 2025-3-23 14:39
Enteropathy-Associated T-Cell Lymphomas, that primarily present in the intestine and were previously collectively termed EATL. Given their distinct immunohistochemistry, mutational profile, and epidemiology, they were formally separated in 2016. Many patients present with an acute abdomen and are diagnosed during laparotomy. While outcome作者: Hangar 時(shí)間: 2025-3-23 18:33
Hepatosplenic T-Cell Lymphoma,ggressive, morbid, or fatal clinical course. Here we review the molecular/biologic basis as well as salient clinical features, diagnostic criteria, and current treatment pathways in this disease. Lastly, we describe potential ways forward for improving the outcome in this dreaded disease based upon 作者: HERE 時(shí)間: 2025-3-23 23:35
,Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome,ll review the most common classifications of CTCL, which include mycosis fungoides (MF), MF variants, and Sézary syndrome (SS). Clinical and pathologic staging systems will be discussed in detail along with the implication of staging on clinical outcomes. Current therapy approaches consist of topica作者: 雀斑 時(shí)間: 2025-3-24 03:27 作者: 細(xì)胞 時(shí)間: 2025-3-24 07:47
http://image.papertrans.cn/n/image/668467.jpg作者: canonical 時(shí)間: 2025-3-24 12:21 作者: ANTE 時(shí)間: 2025-3-24 17:59
The Hematopathology and Diagnostic Challenges of Rare Lymphomas,erscore the need for continued clinical and biologic investigation and a careful interdisciplinary approach to patient care. This chapter introduces the complexity and nuance involved in the diagnosis of lymphoma. There will be a particular emphasis on uncommon lymphoma subtypes and diagnostic pitfalls.作者: quiet-sleep 時(shí)間: 2025-3-24 19:31
Christopher DittusDiscusses the clinical presentation, diagnosis, and treatment approach to rare lymphomas.Focuses on new diagnostic approaches, novel chemotherapy combinations, and new treatment modalities with novel 作者: CRAB 時(shí)間: 2025-3-24 23:18 作者: Prosaic 時(shí)間: 2025-3-25 05:10
Anaplastic Large Cell Lymphoma,nts targeting the universally expressed surface receptor on ALCL cells, CD30, and the ALK tyrosine kinase receptor inhibitors have provided patients with relapsed or refractory ALCL more effective treatment options.作者: Lymphocyte 時(shí)間: 2025-3-25 09:28
Book 2020 on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule 作者: 羽毛長成 時(shí)間: 2025-3-25 15:17
Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,onmalignant tissues, CD30 has become the focus for innovative therapeutic advances (Horie, Semin Immunol 10(6):457–470, 1998). This chapter will focus on first reviewing the standard of care for CD30+ lymphomas and then describing the recent developments in CD30-directed immunotherapy.作者: 外來 時(shí)間: 2025-3-25 17:21 作者: HILAR 時(shí)間: 2025-3-25 22:17 作者: 單調(diào)女 時(shí)間: 2025-3-26 00:57 作者: catagen 時(shí)間: 2025-3-26 06:38
Novel Agents in Primary Central Nervous System Lymphoma,ivolumab, and lenalidomide have shown promise in PCNSL. Future directions will include larger studies with these agents, as well as combination studies with novel agents and conventional chemotherapy.作者: BRAVE 時(shí)間: 2025-3-26 10:41 作者: Enrage 時(shí)間: 2025-3-26 15:15
Extranodal NK/T-Cell Lymphoma,ocalized disease include concurrent, sandwich, or sequential chemoradiation. Advanced stage and extranodal disease are treated with chemotherapy. The overall prognosis for ENKTCL has improved with asparaginase-based chemotherapy. In the relapsed and/or refractory setting, several promising novel agents are currently under investigation.作者: vascular 時(shí)間: 2025-3-26 19:02
Enteropathy-Associated T-Cell Lymphomas,s are significantly better for those who receive anthracycline-based chemotherapy, some patients are not candidates for systemic therapy and have particularly poor outcomes. There is no standard approach to the management of EATL and MEITL. Novel therapies hold promise for the future.作者: 知識(shí)分子 時(shí)間: 2025-3-26 23:15 作者: 有害處 時(shí)間: 2025-3-27 03:11
Book 2020inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents,?.Novel Therapeutics for Rare Lymphomas.?covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas..作者: facilitate 時(shí)間: 2025-3-27 09:16
,Novel Therapeutics in the?Management of Waldenstr?m Macroglobulinemia, have led to improvements in diagnosis, prognostication, and treatment. Better understanding of the pathophysiology of WM has enabled the development of many more targeted therapies that are better tolerated and potentially more effective options for patients with this disease.作者: recession 時(shí)間: 2025-3-27 11:36 作者: LATHE 時(shí)間: 2025-3-27 15:46 作者: 佛刊 時(shí)間: 2025-3-27 18:03
e types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents,?.Novel Therapeutics for Rare Lymphomas.?covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas..978-3-030-25612-8978-3-030-25610-4作者: unstable-angina 時(shí)間: 2025-3-27 23:15
Christin B. DeStefano,Kieron Dunleavy,Catherine Lai作者: perjury 時(shí)間: 2025-3-28 04:37 作者: Spinous-Process 時(shí)間: 2025-3-28 08:17 作者: Cytology 時(shí)間: 2025-3-28 13:12
the solutions to the readers and writer problem were becoming complex; too complex to feel comfortable about the correctness of the solution without extensive analysis. While coding conventions like split-binary semaphores and baton passing give a formal design approach, the resulting programs are s作者: 壯觀的游行 時(shí)間: 2025-3-28 18:39
Haiyuan Wang,Zhisheng Huang,Ning Zhong,Jiajin Huang,Yuzhong Han,Feng Zhang of localized waves at the surfaces of isotropic elastic media. Lattice dynamics of solids had its beginnings in the pioneering work of Born and von Kármán and Debye in 1913, and for the next half a century investigations concentrated mainly on the dynamics of infinite solids. It was only about a qu作者: 競(jìng)選運(yùn)動(dòng) 時(shí)間: 2025-3-28 19:24 作者: transdermal 時(shí)間: 2025-3-28 23:41
Formation of Digital Marketing in Targeted Advertising. On the one hand, targeted advertising is based on the principles of bid management, bid management, the need to regulate targeting, and SPS models. On the other hand, targeted advertising provides for a wide coverage, a wide range of visions, and an increase in search demand. Targeted advertising 作者: Additive 時(shí)間: 2025-3-29 04:38 作者: resilience 時(shí)間: 2025-3-29 10:57 作者: 思想流動(dòng) 時(shí)間: 2025-3-29 12:48 作者: 幸福愉悅感 時(shí)間: 2025-3-29 18:41
Bui Dan Thanh,Nguyen Ngoc Huyenion zu einem bestimmten Zeitpunkt zu erfassen. Zum anderen kann die Beziehung zwischen dem Problem, mit dem die Familie konfrontiert ist, und den famili?ren Interaktionen verdeutlicht werden. Beiden Zielen der Familiendiagnostik versucht die Methodik der Familienskulptur (Duhl et al.1973) gerecht zu werden.作者: GUEER 時(shí)間: 2025-3-29 21:49 作者: 腫塊 時(shí)間: 2025-3-30 02:10 作者: 圓柱 時(shí)間: 2025-3-30 06:03
Rainer Bruggemann,Adalbert Kerber dem Artikel ?Musikwissenschaft? in der neuen MGG. steht au?er Zweifel, da? ?die Korrumpierung durch den Nationalsozialismus die westdeutsche Musikwissenschaft nach 1945 auch intellektuell noch besch?digte?; der Zweifel daran ist selbst Teil dieser Besch?digung. Bestünde er zu Recht, verl?re die Bes作者: 性滿足 時(shí)間: 2025-3-30 10:13
Xu Ruisong,Xu Houshen,Ye Suqun,Lu Huiping,Zhang Lixia novel treatment approach herein referred to as nanotechnology, using nanoparticles. Because of their versatile nature and nanoscale size (1–100?nm), nanoparticles have primarily been able to ameliorate the balance between the toxicity and therapeutic efficacy of conjugated or encapsulated anticance作者: 先兆 時(shí)間: 2025-3-30 15:02
Intracellular Staining with Nickel Chloride,n circumstances where one method is difficult to apply, another may sometimes be substituted. In this article another variation on established methods is described, the use of nickel instead of cobalt ions for injection.作者: Musket 時(shí)間: 2025-3-30 18:19 作者: oxidize 時(shí)間: 2025-3-30 21:22 作者: Charade 時(shí)間: 2025-3-31 04:54 作者: 制定 時(shí)間: 2025-3-31 07:56
